This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Clinical Data, Mannkind and Thanks!

Meantime, the guessing game over the FDA's Afrezza decision continues. On Thursday, JMP Securities reiterated its buy rating and $11 price target on the grounds that there's a 40% chance for a full Afrezza approval on Dec. 29.

"Furthermore, the JPM Securities note continues, "even should a second CRL [Complete Response Letter] be issued, we believe the most likely scenario would not involve a requirement for new, long-term clinical trials (30% probability), based on which we believe the stock would trade in the $8-10 range. We anticipate that the focus for a CRL would be on REMS [risk management plan] and/or the submission of the commercial delivery device and not pulmonary safety or efficacy concerns…"

Diabetic Investor's David Kliff told his newsletter subscribers that Afrezza has less than a 50% chance of getting FDA approval and he recommended banking trading profits ahead of the decision.

My 15 Biotech Stock Predictions for 2011 column provoked some typical yet comedic responses from fans and foes alike, some of who had their own 2011 predictions.

Steveh800 predicts, "A.F. continues to be paid by Wall Street Hedge Funds to bash the stocks in their favor."

Matt writes, "Adam doesn't get a Christmas card from Anna Gluskin (again), but Jim Bianco sends him a lump of coal."

Adamsfriend says, "Adam will be seen making out with Jerry Springer in 2011."

Ruggerschr is angry. "Adam, you are so obviously a schill working for Cramer and his Hedge fund cronies. At least when you go to prison for your dastardly deeds, you will have lots of practice being other people's [Bleep]!"

Nealhugh predicts, "Delcath Systems will rise and FDA approval by Summer 2011."

Rds_1 says, "Adam will be a permanent fixture on The Walking Dead and give up his Street job!"

Mn_vestor has a new biotech business idea: "Biotech startup 'Greymatter' attempts to inject a brain into the skull of Adam Feuerstein. Alas, the attempt fails and he is forced to continue his career as a writer for the Street."

Joe predicts, "Adam will be in an orange jumpsuit." While pdgcwood adds, "And a name change to Shirley."

As I said above, I love you all.

That's a wrap. The Biotech Stock Mailbag is now on a short hiatus, returning Jan. 7, 2011. Keep those emails and tweets coming.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
5 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ABT $37.13 2.20%
DEPO $16.05 -0.12%
DCTH $0.27 3.30%
MNKD $0.97 5.40%
PFE $29.35 0.76%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs